This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines.
According to the ministry’s press release (in French), the price decrease for the drugs Harvoni and Sovaldi is described as “very substantial.” New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for the treatment of hepatitis C, it said.
The new prices will allow continued universal access to hepatitis C for patients in France, the release said. Hepatitis C treatments are integrally supported by the French social security system, which will benefit from those new prices, it added.